241 related articles for article (PubMed ID: 19055809)
1. Integrated multi-level quality control for proteomic profiling studies using mass spectrometry.
Cairns DA; Perkins DN; Stanley AJ; Thompson D; Barrett JH; Selby PJ; Banks RE
BMC Bioinformatics; 2008 Dec; 9():519. PubMed ID: 19055809
[TBL] [Abstract][Full Text] [Related]
2. Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS).
Hong H; Dragan Y; Epstein J; Teitel C; Chen B; Xie Q; Fang H; Shi L; Perkins R; Tong W
BMC Bioinformatics; 2005 Jul; 6 Suppl 2(Suppl 2):S5. PubMed ID: 16026602
[TBL] [Abstract][Full Text] [Related]
3. Identification of protein biomarkers in Dupuytren's contracture using surface enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS).
O'Gorman D; Howard JC; Varallo VM; Cadieux P; Bowley E; McLean K; Pak BJ; Gan BS
Clin Invest Med; 2006 Jun; 29(3):136-45. PubMed ID: 17058431
[TBL] [Abstract][Full Text] [Related]
4. MALDI/SELDI protein profiling of serum for the identification of cancer biomarkers.
Cazares LH; Diaz JI; Drake RR; Semmes OJ
Methods Mol Biol; 2008; 428():125-40. PubMed ID: 18287771
[TBL] [Abstract][Full Text] [Related]
5. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry.
Liu XP; Shen J; Li ZF; Yan L; Gu J
Cancer Invest; 2006 Dec; 24(8):747-53. PubMed ID: 17162557
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.
Semmes OJ; Feng Z; Adam BL; Banez LL; Bigbee WL; Campos D; Cazares LH; Chan DW; Grizzle WE; Izbicka E; Kagan J; Malik G; McLerran D; Moul JW; Partin A; Prasanna P; Rosenzweig J; Sokoll LJ; Srivastava S; Srivastava S; Thompson I; Welsh MJ; White N; Winget M; Yasui Y; Zhang Z; Zhu L
Clin Chem; 2005 Jan; 51(1):102-12. PubMed ID: 15613711
[TBL] [Abstract][Full Text] [Related]
7. Proteomic profiling of ovine serum by SELDI-TOF MS: optimisation, reproducibility and feasibility of biomarker discovery using routinely collected samples.
Zhong L; Taylor DL; Whittington RJ
Comp Immunol Microbiol Infect Dis; 2010 Jan; 33(1):47-63. PubMed ID: 18775566
[TBL] [Abstract][Full Text] [Related]
8. Application of serum SELDI proteomic patterns in diagnosis of lung cancer.
Yang SY; Xiao XY; Zhang WG; Zhang LJ; Zhang W; Zhou B; Chen G; He DC
BMC Cancer; 2005 Jul; 5():83. PubMed ID: 16029516
[TBL] [Abstract][Full Text] [Related]
9. SELDI-TOF-MS of saliva: methodology and pre-treatment effects.
Schipper R; Loof A; de Groot J; Harthoorn L; Dransfield E; van Heerde W
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Feb; 847(1):45-53. PubMed ID: 17070117
[TBL] [Abstract][Full Text] [Related]
10. In-source decay causes artifacts in SELDI-TOF MS spectra.
Ekblad L; Baldetorp B; Fernö M; Olsson H; Bratt C
J Proteome Res; 2007 Apr; 6(4):1609-14. PubMed ID: 17373843
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry.
Navaglia F; Fogar P; Basso D; Greco E; Padoan A; Tonidandel L; Fadi E; Zambon CF; Bozzato D; Moz S; Seraglia R; Pedrazzoli S; Plebani M
Clin Chem Lab Med; 2009; 47(6):713-23. PubMed ID: 19426140
[TBL] [Abstract][Full Text] [Related]
12. Proteomic approaches by SELDI and MALDI-TOF/MS for CTL analysis.
Papale M; Rocchetti MT
Methods Mol Biol; 2014; 1186():233-42. PubMed ID: 25149310
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkers.
Rai AJ; Stemmer PM; Zhang Z; Adam BL; Morgan WT; Caffrey RE; Podust VN; Patel M; Lim LY; Shipulina NV; Chan DW; Semmes OJ; Leung HC
Proteomics; 2005 Aug; 5(13):3467-74. PubMed ID: 16052624
[TBL] [Abstract][Full Text] [Related]
14. Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer.
Wang Q; Shen J; Li ZF; Jie JZ; Wang WY; Wang J; Zhang ZT; Li ZX; Yan L; Gu J
BMC Cancer; 2009 Aug; 9():287. PubMed ID: 19689818
[TBL] [Abstract][Full Text] [Related]
15. Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery.
Seibert V; Ebert MP; Buschmann T
Brief Funct Genomic Proteomic; 2005 May; 4(1):16-26. PubMed ID: 15975261
[TBL] [Abstract][Full Text] [Related]
16. Surface-enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS): a new proteomic urinary test for patients with urolithiasis.
Cadieux PA; Beiko DT; Watterson JD; Burton JP; Howard JC; Knudsen BE; Gan BS; McCormick JK; Chambers AF; Denstedt JD; Reid G
J Clin Lab Anal; 2004; 18(3):170-5. PubMed ID: 15103681
[TBL] [Abstract][Full Text] [Related]
17. Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression.
Brozkova K; Budinska E; Bouchal P; Hernychova L; Knoflickova D; Valik D; Vyzula R; Vojtesek B; Nenutil R
Breast Cancer Res; 2008; 10(3):R48. PubMed ID: 18510725
[TBL] [Abstract][Full Text] [Related]
18. Proteomic profiling of intact mycobacteria by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
Hettick JM; Kashon ML; Simpson JP; Siegel PD; Mazurek GH; Weissman DN
Anal Chem; 2004 Oct; 76(19):5769-76. PubMed ID: 15456297
[TBL] [Abstract][Full Text] [Related]
19. Geena 2, improved automated analysis of MALDI/TOF mass spectra.
Romano P; Profumo A; Rocco M; Mangerini R; Ferri F; Facchiano A
BMC Bioinformatics; 2016 Mar; 17 Suppl 4(Suppl 4):61. PubMed ID: 26961516
[TBL] [Abstract][Full Text] [Related]
20. Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples.
Freed GL; Cazares LH; Fichandler CE; Fuller TW; Sawyer CA; Stack BC; Schraff S; Semmes OJ; Wadsworth JT; Drake RR
Laryngoscope; 2008 Jan; 118(1):61-8. PubMed ID: 18043497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
